Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
about
Enhancement of stress resilience through histone deacetylase 6-mediated regulation of glucocorticoid receptor chaperone dynamics.Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth DiseasePrimary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cellsTop-Down Control of Serotonin Systems by the Prefrontal Cortex: A Path toward Restored Socioemotional Function in DepressionNew HDAC6-mediated deacetylation sites of tubulin in the mouse brain identified by quantitative mass spectrometryRepetitive transcranial magnetic stimulation induces long-lasting changes in protein expression and histone acetylationHDAC6 Regulates the Chaperone-Mediated Autophagy to Prevent Oxidative Damage in Injured Neurons after Experimental Spinal Cord Injury.Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulationWhy Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?Cigarette Smoke Disrupted Lung Endothelial Barrier Integrity and Increased Susceptibility to Acute Lung Injury via Histone Deacetylase 6Control of cortex development by ULK4, a rare risk gene for mental disorders including schizophreniaEpigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Histone deacetylase 6 in health and disease.Dissecting structure-activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation.Unfolding the pathogenesis of scleroderma through genomics and epigenomics.Epigenetics of Autism Spectrum Disorder.Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production.Epigenetic drug discovery: breaking through the immune barrier.The acetyl code in rheumatoid arthritis and other rheumatic diseases.Psychiatric behaviors associated with cytoskeletal defects in radial neuronal migration.HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated DeoxyfluorinationFluoxetine induces apoptosis through endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in SK-N-BE(2)-M17 human neuroblastoma cells.Effects of Cigarette Smoke on Pulmonary Endothelial Cells.Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.Modulation of antitumor immunity with histone deacetylase inhibitors.Disruption of lipid-raft localized Gαs/tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds.
P2860
Q27328366-B95F58FF-E001-429E-AAE1-1954BA760F2EQ30401432-51DA63B7-F5D8-47A2-8062-9EA38966634BQ33586017-1D256584-99A2-4DBE-8B1B-C06B51FAD792Q33894574-0AEF7C00-0451-4200-A135-FC95D58D825EQ35213084-6D9995BB-459E-4F52-8CF7-1E2EAB8EC2D6Q35858540-88E03B92-EB68-45C1-B534-99CBDC46386FQ36298070-7ADE960F-4CEE-4191-AA31-4321F2FE9851Q36301103-857E7169-5A18-421E-9DF3-F0DE67DD2AF5Q36327985-DCCE1EA8-BEC1-442D-924D-88E444BBB260Q36500444-0DD3F47B-DFA0-40DE-95D8-B8A52CE2DFF1Q36614119-38C7E032-671C-4327-88C8-31849A4B4AB0Q37088228-87A1B528-5AC6-4B8E-B4AD-0657A331C969Q37285259-872728C2-E12E-4EB9-B0BB-35392506CDC1Q38233723-896604E5-0753-43CF-847C-09B7F1F9C0AEQ38240733-34C5C656-6039-4295-8762-D73B0A3B7E67Q38357741-EEC92DE5-F822-460D-AFA6-52B0C950DB75Q38418571-9D7F557F-A6F6-464A-A9C4-D65EED8F2FACQ38681645-4E477F9E-7C19-44CF-9F24-5C2187B28221Q38681930-93917851-43BF-4CD8-B39E-EFFC31ADDF82Q38979974-E871F5EC-14B5-4F68-B9D8-F78F130032E0Q38986705-A7BFC2FB-53BF-40F0-B3B8-1F1997EECD97Q39094945-E2B3BDDB-DC26-4D06-90E7-708E57DC6233Q39314105-A0D912D3-E3DD-4766-8802-9983CC5614B2Q40972077-DAE2FDA0-DAEB-4D08-B695-52FF09D77422Q42367165-8D2D2DC1-ACF3-4B76-BADE-3D6AC8EEA7E0Q46344924-1F18467E-08BC-4949-B601-DA2A69CAAB73Q47652532-B23654C3-0AAC-42A4-9FEA-D7DD4FCA0456Q49149016-57A7C8C9-85DF-44FD-8AD1-62D49140A9EBQ49557954-69F2F169-0F72-4C63-9B5C-993234979EC2Q49788875-F261D1BC-206F-46D5-8879-DBC42BAF083E
P2860
Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antidepressant-like properties ...... mproved brain bioavailability.
@en
Antidepressant-like properties ...... mproved brain bioavailability.
@nl
type
label
Antidepressant-like properties ...... mproved brain bioavailability.
@en
Antidepressant-like properties ...... mproved brain bioavailability.
@nl
prefLabel
Antidepressant-like properties ...... mproved brain bioavailability.
@en
Antidepressant-like properties ...... mproved brain bioavailability.
@nl
P2093
P2860
P356
P1476
Antidepressant-like properties ...... mproved brain bioavailability.
@en
P2093
Bridgin G Lee
Janette Boulden
Jeanine Jochems
John H Van Duzer
Julie A Blendy
Matthew Jarpe
Olivier Berton
Ralph Mazitschek
Simon Jones
P2860
P2888
P304
P356
10.1038/NPP.2013.207
P407
P577
2013-08-19T00:00:00Z